Clinical Research Directory
Browse clinical research sites, groups, and studies.
Smoking Cessation Treatment for Head & Neck Cancer Patients
Sponsor: M.D. Anderson Cancer Center
Summary
This is Part 1 of a 2-part research study. The goal of this part of the study is to plan and test an investigational type of counseling called Acceptance and Commitment Therapy, for use in patients who have or had head and neck cancer, lung cancer, breast cancer, gastrointestinal cancer, or genitourinary cancer. This part of the study is also designed to train the study counselors how to perform Acceptance and Commitment Therapy. In this part of the study, participants will either receive Acceptance and Commitment Therapy or the standard type of counseling, called Motivational and Behavioral Counseling. This is Part 2 of a 2-part research study. In both parts of the study, participants receive either an investigational type of counseling (Acceptance and Commitment Therapy) or a standard type of counseling (Motivational and Behavioral Counseling). Part 1 was also designed to train the study counselors how to perform Acceptance and Commitment Therapy. The goal of Part 2 is to compare Acceptance and Commitment Therapy against Motivational and Behavioral Counseling. Researchers want to learn which type of counseling may be more effective in helping patients to stop smoking. These types of counseling will be tested in patients who have or had head and neck cancer, lung cancer, breast cancer, gastrointestinal cancer, or genitourinary cancer.
Official title: Smoking Cessation Treatment for Head & Neck Cancer Patients: Acceptance and Commitment Therapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
51
Start Date
2010-03-24
Completion Date
2027-09-30
Last Updated
2025-11-10
Healthy Volunteers
No
Conditions
Interventions
Acceptance and Commitment Therapy
6 x 60-minute counseling sessions delivered over a 5-week period
Motivational and Behavioral Counseling
6 x 60-minute counseling sessions delivered over a 5-week period
Varenicline
2 mg daily for 12 weeks
Locations (1)
University of Texas MD Anderson Cancer Center
Houston, Texas, United States